摘要
运用免疫组化S－P法检测喉鳞癌组织中nm23－H_1单克隆抗体的表达，结果发现：喉癌组织中nm23－H1蛋白表达阳性率为72．9％。nm23－H_1蛋白表达阳性率在伴有颈淋巴结转移的喉癌中低于无颈淋巴结转移喉癌（P＜0．01）；在Ⅲ～Ⅳ期喉癌中亦低于Ⅰ～Ⅱ期喉癌（P＜0．05）。nm23－H_1蛋白表达与喉癌的生长部位和病理分级无关。结合随访分析表明：nm23－H_1蛋白表达阳性患者总体生存率高于阴性表达者（P＜0．01）。提示nm23－H_1基因可能有抑制喉癌颈淋巴结转移和肿瘤组织生长作用，检测其蛋白表达有判断预后价值。
To investigate the expression of nm23-H_1 gene in laryngeal squamous cell carcinoma, immunohistochemistry was carried out with a monoclonal antibody against nm23-H_1. Of 48cancer tessues tested, 35 (72. 9% ) showed a positive immuno-reaction for nm23-H_1. The percentage of nm23-H_1 positivity was significantly lower (P<0.01) in the tumors with cervical lymphnode metastasis than in those without metastasis. Moreover, the percentage of nm23-H_1 positivitywas significantly lower (P<0. 05) in tumors of stages Ⅲ-Ⅳthan in those of stages Ⅰ-Ⅱ. Nosignificant correlation was found between nm23-H_1 expression and tumor sites or histopathologicalgrades. Analyzed with following up date, we found that the overall survival was better (P<0. 01) in patients with nm23-H_1 expression than in those without expression.These results suggestthat nm23-H_1 gene may play a role in the suppression of lymph node metastasis and tumor progression in laryngeal carcinoma, and the expression of nm23-H_1 gene is a useful predictor of prognosis.
出处
《临床耳鼻咽喉科杂志》
CSCD
1998年第6期247-250,共4页
Journal of Clinical Otorhinolaryngology
